Healthcare Industry News: SBRT
News Release - September 22, 2013
Accuray to Showcase Clinical Utilization and Adoption of its Latest Advanced Product Platforms at ASTRO 2013World's Largest Annual Gathering of the Radiation Oncology Community Provides Multiple Opportunities to Learn about the CyberKnife® M6™ Series and the TomoTherapy® H™ Series Systems
SUNNYVALE, Calif. and ATLANTA, Sept. 22, 2013 -- (Healthcare Sales & Marketing Network) -- ASTRO 2013 -- Accuray Incorporated (ARAY) announced today its momentum in gaining adoption for both the new CyberKnife® M6™ Series and TomoTherapy® H™ Series Systems at the 55th Annual American Society for Radiation Oncology (ASTRO) Meeting taking place at the Georgia World Congress Center in Atlanta. Through presentations from leading radiation oncology practitioners and product demonstrations, attendees can gain further knowledge on the clinical capabilities of the CyberKnife M6 Series and TomoTherapy H Series Systems introduced at last year's ASTRO meeting.
Adoption of Accuray's latest advanced product platforms continues to grow, with many cancer centers in the U.S. and in Europe already investing in the technology. U.S. centers include the University of Pittsburgh Medical Center in Pennsylvania, Tulsa Cancer Institute of Oklahoma, Lancaster General Health in Pennsylvania, Spokane CyberKnife & Radiation Oncology Center in Washington and University of Arkansas Medical Sciences in Little Rock. Centers in Europe and Asia include, the European CyberKnife Center Munich-Grosshadern (ECZM) in Munich, Germany, Heidelberg University Hospital in Germany, Erasmus Medical Center (MC), in Rotterdam, the Netherlands, the Centre Oscar Lambret in Lille, France and The Severance Hospital, Yonsei University Healthcare System in Seoul, Korea.
These institutions have successfully implemented the new CyberKnife and TomoTherapy Systems and are experiencing significant benefits, including reduced treatment times, improved treatment plan quality, expanded patient treatment options for the CyberKnife M6 System, and reduced treatment planning time with the TomoHDA System.
"We have seen firsthand that the non-coplanar beam geometry of the CyberKnife M6 System allows us to create high-quality, high-dose distributions that can be delivered with extreme accuracy over a minimum number of treatments allowing us to minimize side effects and preserve our patients' quality of life," said Jeffrey S. Eshleman, M.D., Director of Radiation Oncology, Ann B. Barshinger Cancer Institute of Lancaster General Health in Pennsylvania. "We are focused on providing the most effective and efficient SRS/SBRT treatment option and the CyberKnife System has excelled in its ability to track and treat moving targets while sparing nearby critical structures and healthy tissue."
"In its first three months of clinical use at our center, the TomoHDA System has proven to be a versatile and efficient addition to our department," said Prof. Eric Lartigau, M.D., Ph.D., Centre Oscar Lambret, Lille, France. "The system allows rapid treatment planning and high-precision dose delivery, a combination of features that lends itself well to breast cancer cases and helps improve overall quality, patient throughput and workflow for the department."
"In an effort to enhance the capabilities of the TomoTherapy and CyberKnife Systems, our guiding mission is always to provide patients with the best possible treatment outcomes," said Joshua H. Levine, president and chief executive officer of Accuray. "The feedback we have received from leading radiation oncology practitioners validates the decision to further invest in our unique product offerings. We look forward to our invaluable collaborators informing colleagues of their experiences and learnings to-date at this year's ASTRO meeting."
There will be many opportunities to learn about Accuray's advanced radiation oncology treatment solutions at the 2013 ASTRO annual meeting, including:
Clinical research presentations: Clinical presentations will be delivered in scientific sessions highlighting clinical outcomes obtained with real-time tracking of target motion and automatic correction of beam aim with Accuray's CyberKnife System. Additionally, presentations will be delivered on the clinical benefits of exceptional treatment plan quality and accurate megavoltage CT-guided patient setup with the TomoTherapy System.
Industry expert theater: Accuray will host a symposium at the ASTRO Industry Expert Theater titled, "Accuray: Dynamic Technology in Motion," presented by Alexandra Jensen, M.D., MSc., University of Heidelberg and Prof. Alexander Muacevic, M.D., European CyberKnife Center Munich on Sunday, September 22 from 12:45 p.m. – 1:45 p.m. ET in the Exhibit Hall. These luminaries will share firsthand perspectives on the clinical benefits of the new CyberKnife M6 Series and TomoTherapy H Series Systems. Lunch will be served.
In-booth presentations and product demonstrations: While the exhibit hall is open, Accuray will offer in-booth presentations (booth #1842) and product demonstrations on new features including VoLO™ Planning and TomoEDGE™ Dynamic Jaws for the TomoHDA System and the Multileaf Collimator (MLC) for the CyberKnife M6 System. The exhibit hall will be open Sunday, September 22 – Tuesday, September 24 from 10:00 a.m. – 5:00 p.m. ET each day. For those interested in registering for product demonstrations in advance, please visit http://accuraybooth1842atlanta.com/.
Investor meeting: Accuray's management team will host a breakfast meeting, from 7:00 a.m. to 9:00 a.m. ET on Monday, September 23 at the OMNI Hotel, 100 CNN Center Atlanta, in the International Ballroom F. The presentation will provide a review of Accuray's leading-edge technology platforms of radiation therapy and radiosurgery treatments. Attendees are asked to register online: https://www.regonline.com/Register/Checkin.aspx?EventID=1281872. A live webcast of the presentation will be available online from the Investor Relations page of the Company's website at http://www.accuray.com/investors.
Follow the Accuray Twitter handle, @Accuray, for real-time updates from the ASTRO show floor. To schedule a briefing with an Accuray executive, please contact Rebecca Phillips, email@example.com or +1 (408) 242-3831.
Accuray Incorporated (ARAY), is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to adoption of new technologies, clinical experience, clinical applications, clinical results, and the Company's leadership position in radiation oncology innovation and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on August 29, 2013, and as updated periodically by our other filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAccuray Launches Synchrony(R) Motion Tracking and Correction Technology for the Radixact(R) System
Phase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer
Accuray and China Isotope and Radiation Corporation Enter Joint Venture Contract to Manufacture and Sell Radiation Oncology Systems in China